ClinicalTrials.gg
Enrolling by invitationNCT05653310Updated Jul 16, 2026

Tradipitant for Functional Dyspepsia

A Phase 2 interventional study of Tradipitant and Placebo in Functional Dyspepsia, sponsored by Xiao Jing (Iris) Wang. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Xiao Jing (Iris) Wang · Phase 2, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Dyspepsia with a site in United States — 14 open to participants now, 18 under way, 1 of them phase 3. Dyspepsia · United States.

Planned enrollment
28th of 67
60 · median 50
Started
2023
with 3 others
Phase 2
8 of 77
2 open now
Primary completion
2027-03
later than 5 of 17 live
Registered
62nd of 77
by date

Among the 77 studies in Dyspepsia with a site in United States, this one is the 28th largest by planned enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2023, is one of 8 in phase 2, reaches primary completion later than 5 of the 17 other live ones, and was the 62nd registered.

Dyspepsia

373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

14 of the 77 studies in Dyspepsia with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Dyspepsia with a site in United States, or all of them as a file.
02

Study summary

To evaluate the effects of tradipitant relative to placebo on gastric motor functions, satiation, and postprandial symptoms in patients with functional dyspepsia.

03

Conditions studied

  • Functional Dyspepsia

Browse trials for

Keywords

  • tradipitant
  • NK-1 antagonist
  • neurokinin 1 receptor
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written consent
  • (BMI) of 18-35 kg/m2
  • Absence of other diseases which could interfere with interpretation of study results

Exclusion criteria

Exclusion Criteria:

  • Current H. pylori infection
  • Pregnancy or nursing
  • Recent history of Alcohol Use Disorder or Substance Use Disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Tradipitant

    Oral Capsule

    Drug: Tradipitant

  • Placebo comparator
    Placebo

    Oral Capsule

    Drug: Placebo

Interventions

  • Tradipitant Capsule

  • DrugPlacebo

    Placebo Capsule

06

What researchers measure

Primary outcomes

  1. Accommodation gastric volumes measured by single photon emission computed tomography (SPECT)

    Time frame: 4 Weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Mar 2027, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2022
First posted
Dec 16, 2022
StartActual
Feb 9, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05653310
Lead sponsor
Xiao Jing (Iris) Wang
Collaborators
Mayo Clinic
Responsible party
Xiao Jing (Iris) Wang (Regulatory Sponsor and Principal Investigator, Mayo Clinic) — Sponsor-investigator
First posted
Dec 16, 2022
Start date
Feb 9, 2023
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Xiao Jing (Iris) Wang, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion